Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

By E. Abraham, P. Laterre, R. Garg, H. Levy, D. Talwar, B. Trzaskoma, B. François, J. Guy, M. Brückmann, Á. Réa-Neto and 6 more. New England Journal of Medicine, 2005

807 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Immunology

View Paper: https://www.semanticscholar.org/paper/319e2aacb0d5800acb4c8e653196d065186c6246

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Immunology

Citations in the corpus

The Pathogenesis of Sepsis (2011, background): “1% and was associated with better long-term organ function in severely septic patients has been tempered by the significant bleeding risk associated with drotrecogin alfa in almost all studies (58), lack of beneficial effects in children (55), and lack of benefit in patients with severe sepsis but l”
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 (2007, neutral): “DRESS (stopped early for futility) (116).”
Drotrecogin alfa (activated) in adults with septic shock. (2012, methodology): “Our findings are consistent with results of the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) and the Resolution of Organ Failure in Pediatric Patients with Severe Sepsis (RESOLVE) trials, which showed that DrotAA did not reduce mortality in children or adults”
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 (2013, background): “by regulatory agencies) had shown it ineffective in less severely ill patients with severe sepsis as well as in children [229, 230].”
Guidelines for the diagnosis and management of disseminated intravascular coagulation (2009, neutral): “Of note, activated protein C appears to be relatively more effective in higher disease severity groups and a prospective trial in septic patients with relatively low disease severity did not show any beneﬁt of protein C (Abraham et al , 2005).”
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010, background): “Activated protein C has been shown to decrease mortality for patients with severe sepsis but cannot be advised for those with a low risk of death due to increased bleeding complications (1, 27).”
Pathophysiology of sepsis. (2007, background): “Follow-up studies demonstrated that patients at low risk for death had no improvement in survival and had a significantly increased risk of bleeding if treated with activated protein C.(14)”
Adjunctive Glucocorticoid Therapy in Patients with Septic Shock (2018, methodology): “‡ Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II are assessed on a scale from 0 to 71, with higher scores indicating a higher risk of death (a score of ≥25 has been used as a cutoff point to identify patients at a higher risk for death).(23-25) § The values for baseline the”